Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Experimental Human Malaria Infection by PfSPZ

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01086917
Recruitment Status : Completed
First Posted : March 15, 2010
Last Update Posted : April 21, 2015
Sponsor:
Collaborator:
Radboud University
Information provided by (Responsible Party):
Sanaria Inc.

Brief Summary:
The study is a single center, varied dose, open label study. A maximum of eighteen volunteers will be exposed to live NF54 P. falciparum sporozoites (PfSPZ Challenge) by intradermal injection. Volunteers will be divided into three groups of 6 volunteers, each group spaced 25 days apart (21 days after the last challenge of the last volunteer from the previous dose group).

Condition or disease Intervention/treatment Phase
Malaria Biological: PfSPZ Challenge Phase 1

Detailed Description:

In every group on day 1, two volunteers will be injected. On day 3 the remaining four volunteers of the group will be injected. Injections in subsequent volunteers are always spaced at least one hour apart in any group. Injection of subsequent (groups of) volunteers will only commence if the previous injection was shown to be safe. Three different doses of PfSPZ will be administered: a dose of 2,500 PfSPZ Challenge (Group 1); a dose of 10,000 PfSPZ Challenge (Group 2) if not all volunteers become thick smear positive (TS+) in Group 1; and a dose of 25,000 PfSPZ Challenge (Group 3) if there is not 100% TS+ in Group 2. If all volunteers in Group 1 (2,500 PfSPZ Challenge) become thick smear positive, then Group 2a will receive 1,000 PfSPZ Challenge. If all volunteers in Group 2a become TS+, the volunteers in Group 3a will receive 500 PfSPZ Challenge. If all volunteers in Group 2 (10,000 PfSPZ Challenge) become TS+, Group 3b will receive 5,000 PfSPZ. If less than 100% of volunteers in Group 2a (1,000 PfSPZ Challenge) become TS+ then Group 3c will receive 1,750 PfSPZ Challenge.

The clinical, biological, parasitological and immunological data of these groups' volunteers will be compared. Volunteers and the investigator will not be blinded, but the laboratory personnel will be blinded.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Experimental Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites (PfSPZ Challenge)
Study Start Date : August 2010
Actual Primary Completion Date : February 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: Group 1
to receive a dose of 2,500 PfSPZ Challenge
Biological: PfSPZ Challenge
each volunteer to receive a single dose
Other Name: aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Experimental: Group 2
to receive a dose of 10,000 PfSPZ Challenge
Biological: PfSPZ Challenge
each volunteer to receive a single dose
Other Name: aseptic, purified, cryopreserved Plasmodium falciparum sporozoites

Experimental: Group 3
to receive a dose of 25,000 PfSPZ Challenge
Biological: PfSPZ Challenge
each volunteer to receive a single dose
Other Name: aseptic, purified, cryopreserved Plasmodium falciparum sporozoites




Primary Outcome Measures :
  1. Number of volunteers with Plasmodium falciparum Infection [ Time Frame: Upto 7 months ]
    To achieve a 100% infection rate of human volunteers by intradermal injection of aseptic, purified, cryopreserved Pf sporozoites (PfSPZ Challenge)as measured by 100% thick smear positivity (thick blood smears) of all volunteers from one group


Secondary Outcome Measures :
  1. Kinetics of infection [ Time Frame: Upto 7 months ]

    To compare parasite kinetics between different doses of intradermal injection of PfSPZ Challenge as measured by:

    • A significant difference in time of thick smear positivity between the groups of volunteers
    • A significant quantitative difference in parasitemia as measured by retrospective PCR between the groups of volunteers
    • A significant difference in kinetics of parasitemia between the groups of volunteers as measured by retrospective PCR
    • A difference in occurrence or intensity of signs or symptoms between the groups of volunteers



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 34 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age > 18 and < 35 years healthy volunteers (males or females)
  2. Good health based on history and clinical examination
  3. Negative pregnancy test
  4. Use of adequate contraception for females
  5. All volunteers must sign the informed consent form demonstrating their understanding of the meaning and procedures of the study
  6. Volunteer agrees to inform the general practitioner and agrees to sign a request to release medical information concerning contra-indications for participation in the study
  7. Willingness to undergo a Pf sporozoite challenge
  8. For volunteers not living in Nijmegen: agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 till 3 days after treatment)
  9. Reachable (24/7) by mobile phone during the whole study period
  10. Living with a third party that could contact the clinicians in case of alteration of consciousness or agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 till 3 days after treatment)
  11. Available to attend all study visits
  12. Agreement to refrain from blood donation to Sanquin or for other purposes, during the study period until day 140.
  13. Willingness to undergo HIV, hepatitis B and hepatitis C tests
  14. Negative urine toxicology screening test at screening visit and day before challenge
  15. Willingness to take a curative regimen of Malarone®

Exclusion Criteria:

  1. History of malaria
  2. Plans to travel to malaria endemic areas during the 140 day study period
  3. Plans to travel outside of the Netherlands during day 0-28 of the study
  4. Previous participation in any malaria vaccine study and/or positive serology for Pf
  5. Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers
  6. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
  7. History of arrhythmias or prolonged QT-interval
  8. Positive family history in 1st and 2nd degree relatives for cardiac disease < 50 years old
  9. An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system
  10. Clinically significant abnormalities in electrocardiogram (ECG) at screening
  11. Body Mass Index (BMI) below 18 or above 30 kg/m2
  12. Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis
  13. Positive HIV, HBV or HCV tests
  14. Participation in any other clinical study within 30 days prior to the onset of the study
  15. Enrollment in any other clinical study during the study period
  16. Pregnant or lactating women
  17. Volunteers unable to give written informed consent
  18. Volunteers unable to be closely followed for social, geographic or psychological reasons
  19. Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study
  20. A history of psychiatric disease
  21. Known hypersensitivity to anti-malaria drugs
  22. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids are allowed) and during the study period
  23. Contra-indications to Malarone® including treatment taken by the volunteer that interferes with Malarone®
  24. Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia
  25. Co-workers of the departments of Medical Microbiology or Internal Medicine of the Radboud University Nijmegen Medical Centre or Sanaria Inc.
  26. A history of sickle cell anemia, sickle cell trait, thalassemia , thalassemia trait or G6PD deficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01086917


Locations
Layout table for location information
Netherlands
Radboud University Nijmegen Medical Center
Nijmegen, Netherlands, 6500 HB
Sponsors and Collaborators
Sanaria Inc.
Radboud University
Investigators
Layout table for investigator information
Principal Investigator: Robert Sauerwein, Md PhD UMC St Radboud
Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sanaria Inc.
ClinicalTrials.gov Identifier: NCT01086917    
Other Study ID Numbers: TIP2
First Posted: March 15, 2010    Key Record Dates
Last Update Posted: April 21, 2015
Last Verified: April 2015
Keywords provided by Sanaria Inc.:
Malaria Challenge
Plasmodium falciparum
Controlled human malaria infection
PfSPZ Challenge
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Malaria
Protozoan Infections
Parasitic Diseases